Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy

MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics) received a patent for mitigating
erectile dysfunction (ED) as an adverse side effect of radiation therapy
for prostate cancer using their proprietary radioprotectant compound,
BIO 300. Dr. Zeljko Vujaskovic, MD, professor of radiation oncology at
the University of Maryland School of Medicine (UM SOM) and director of
the school’s Division of Translational Radiation Sciences (DTRS); and
Dr. Isabel L. Jackson, PhD, assistant professor in the UM SOM Department
of Radiation Oncology and deputy director of DTRS, are co-inventors.

Prostate cancer is the most common non-skin cancer affecting men in the
U.S. Per the National Cancer Institute, nearly 181,000 men were
diagnosed with prostate cancer in the U.S. in 2016, representing
approximately 20% of all new cancers in men. While survival rates are
high, radiation-induced ED occurs in up to fifty percent of all cases.
There are no approved drugs to mitigate radiation-induced ED.

Preclinical studies completed in collaboration with the University of
Maryland demonstrated that BIO 300 can both mitigate radiation-induced
ED and improve the effectiveness of radiotherapy to kill the tumors.
“Radiation-induced ED remains a devastating consequence of prostate
cancer therapy and influences treatment-related decisions for these
patients,” said Dr. Vujaskovic. “These findings support the advancement
of this novel drug into a human efficacy study.”

BIO 300 is expected to be in a clinical study involving prostate cancer
patients in 2017.

About Humanetics Corporation

Humanetics is a clinical-stage pharmaceutical company engaged in
developing and commercializing products to enhance human health and
wellbeing in markets with urgent and unmet needs with a focus on
radiation modulators for oncology, medical imaging and medical
countermeasure uses.

About the University of Maryland School of Medicine

The University of Maryland School of Medicine is the first public
medical school in the United States and is a leader in accelerating
innovation and discovery in medicine. The School of Medicine is the
founding school of the University of Maryland and works closely with the
University of Maryland Medical Center and Medical System to provide a
research-intensive, academic and clinically-based education.


Humanetics Corporation
Dr. Michael Kaytor, 952-400-0406
Research and Development